Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
公司代碼EVO
公司名稱Evotec SE
上市日期Oct 11, 1999
CEOWojczewski (Christian)
員工數量4827
證券類型Depository Receipt
年結日Oct 11
公司地址Essener Bogen 7
城市HAMBURG
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Germany
郵編22419
電話4940560810
網址https://www.evotec.com/
公司代碼EVO
上市日期Oct 11, 1999
CEOWojczewski (Christian)